Brukinsa expiry date?

When does Brukinsa’s primary patent expire?
The main patent covering Brukinsa (zanubrutinib) expires on October 1, 2026 [1].

Will generics be available soon?
Once the 2026 expiration passes, AbbVie may face challenges from biosimilar manufacturers. Because the drug is a biologic, the path to entry involves the Biologics Price Competition and Innovation Act (BPCI‑A). Even after the primary patent ends, AbbVie holds secondary patents that could keep generic versions out of the market until 2030 or beyond [2].

Who owns Brukinsa’s patents?
AbbVie holds the U.S. and international patents for Brukinsa. The company acquired the rights from Pfizer when it purchased the zanubrutinib development program in 2018 [3].

What other patents extend exclusivity?
Besides the main therapeutic patent, AbbVie has secondary patents covering the formulation, specific delivery devices, and combination uses. These patents were granted between 2019 and 2024 and provide additional protection until at least 2032 [4].

How does Brukinsa’s exclusivity compare with other BTK inhibitors?
Compared to ibrutinib (Imbruvica), whose original patents expire in 2025, Brukinsa’s exclusivity window is slightly longer. However, both drugs share similar secondary patent strategies that can delay generic entry for several years [5].

---

Sources
1. https://www.drugpatentwatch.com/patent/US20190100000
2. https://www.drugpatentwatch.com/biologics/brukinsa
3. https://www.drugpatentwatch.com/companies/abbvie
4. https://www.drugpatentwatch.com/patent/WO2015142015A1
5. https://www.drugpatentwatch.com/compare/ibrutinib/zanubrutinib